Biotek-snakken — Februar 2022
-
Denne ugekommentar dedikerer Helge Larsen til biotech, nærmere bestemt den nedtur, sektoren har oplevet og stadig oplever. Han kigger bl.a. ned i mulige årsager som rentestigninger, sektorrotation - men også over på markedet i USA med NBI-indekset og mekanismerne her. https://www.proinvestor.com/boards/100739/Ugekommentaren-Nedturen-i-biotech
-
Cantargia reports treatment of first non-squamous non-small cell lung cancer patient in new arm of CANFOUR study
https://www.proinvestor.com/index.php?p=debat_1&postid=100767 -
@LP90 - jeg håber ikke INVA får held til deres lille stunt. Vi må håbe de største aktionærer (udover INVA) sætter foden ned. Men altså alt kan ske tilsyneladende...hvis INVA "køber" direktion og bestyrelse med højere lønninger og gode sikrede jobs, ja så ser det tungt ud synes jeg. Jeg har det næsten som da Medarex blev solgt
-
Biogen and Xbrane Announce Commercialization and License Agreement for Proposed Biosimilar Referencing CIMZIA
(Certolizumab pegol) with the Potential to Treat Rheumatoid Arthritis https://xbrane.com/en/mfn_news_en/biogen-and-xbrane-announce-commercialization-and-license-agreement-for-proposed-biosimilar-referencing-cimzia-certolizumab-pegol-with-the-potential-to-treat-rheumatoid-arthritis/ -
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind